|
|
News Breaks
|
November 23, 2009
|
| 09:29 EDT |  | VRX |
| theflyonthewall.com: | Investors may be too bullish on Valeant Pharmaceutical, Barron's says | | Investors may be too optimistic about the potential of Valeant Pharmaceutical's (VRX) epilepsy drug, retigabine, Barron's warns. Retigabine may not be able to compensate for reduced royalties from Valeant's top seller, an antiviral treatment called ribavirin, according to the publication. Meanwhile, Retigabine's side effects caused a large number of patients to withdraw from a clinical study of the drug, Barron's notes. Reference Link :theflyonthewall.com |
|
|
News For VRX From The Last 14 Days Check below for free stories on VRX the last two weeks.
There are 7 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 6, 2012
|
| 08:10 EDT |  | VRX |
| theflyonthewall.com: | Valeant Pharma completes divestiture of generic dermatology products to Mylan | | Valeant Pharmaceuticals (VRX) announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel, or IDP-111, a generic version of Benzaclin, and 5% fluorouracil cream, 5-FU, an authorized generic of Efudex, to Mylan (MYL). This action was required under the consent order issued by the Federal Trade Commission, or FTC, as part of the acquisition of Dermik, a dermatology unit of Sanofi (SNY), which was completed in December 2011. :theflyonthewall.com |
|
|
February 1, 2012
|
| 08:37 EDT | | VRX |
| theflyonthewall.com: | Valeant Pharmaceuticals acquires Probiotica in Brazil | | Valeant Pharmaceuticals announced that Valeant has acquired Probiotica Laboratorios Ltda., a leader in sports nutrition and food supplements in Brazil. Probiotica currently markets a full line of over-the-counter sports nutrition products and other food supplements, with a 30% share of the market. Valeant will acquire Probiotica for R$150M. Net revenue in 2011 was approximately R$80M and double digit growth is expected in 2012. The transaction is expected to be immediately accretive. :theflyonthewall.com |
|
|
January 31, 2012
|
| 11:21 EDT |  | VRX |
|
|
January 30, 2012
|
| 08:40 EDT | | VRX |
| theflyonthewall.com: | Ista board updates strategic review process | | The Board of Directors of ISTA Pharmaceuticals reiterated its commitment to maximizing shareholder value and said it will continue its previously announced review of all strategic options available to the Company. The Board issued its statement in response to a press release from Valeant Pharmaceuticals International (VRX) announcing that Valeant had withdrawn its unsolicited proposal to acquire ISTA. ISTA's review of its strategic options, which the Company publicly announced on December 16, 2011, is advancing expeditiously and in a manner consistent with the Board's fiduciary responsibilities. ISTA is currently in dialogue with a number of parties that have expressed an interest in pursuing a strategic transaction and remains committed to maximizing shareholder value. :theflyonthewall.com |
| | 08:40 EDT | | VRX |
| | 08:02 EDT | | VRX |
| theflyonthewall.com: | Valeant Pharmaceuticals to syndicate senior secured term loan credit facility | | Valeant Pharmaceuticals announced plans to syndicate a $500M senior secured Term Loan B credit facility as a new tranche under its existing senior secured credit facilities to fund repayment of its existing $275M revolving facility and for general corporate purposes, including acquisitions. The Term Loan B loans will mature in 2019 and are expected to have terms that are customary for this type of financing. The facility is expected to close in February 2012, subject to market and other customary conditions. :theflyonthewall.com |
| | 07:46 EDT | | VRX |
| theflyonthewall.com: | Valeant Pharmaceuticals withdraws offer for acquisition of ISTA Pharmaceuticals |
 Subscribe for More Information :theflyonthewall.com |
|
|
|
|
|
